Plain-English translation of NCT04290806 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
SAPHIR is a long-term registry study that collects detailed information about how advanced stomach and esophageal cancers are treated in real-world care. Researchers will follow patients for up to two years, recording which treatments doctors prescribe, how patients respond, and how treatment affects daily quality of life. This study doesn't test a specific new medication—instead, it gathers information from routine cancer care to understand treatment patterns and outcomes across Germany.
Advanced stomach and esophageal cancers are serious conditions, and doctors need better information about which treatment approaches work best and how they affect patients' lives. By collecting detailed records from many patients receiving palliative (comfort-focused) care, this registry will help doctors understand common treatment sequences, identify what works, and ultimately improve care for future patients.
You likely qualify if…
You likely don't qualify if…
When you enroll, the study team will collect information about your health history, cancer details, and previous treatments. Throughout your participation—up to two years—your doctors will continue treating you normally, and researchers will document all treatments you receive, how your cancer responds, any surgeries or radiation therapy, and your outcomes. You'll also be asked to complete questionnaires about your quality of life and how the treatment is affecting you—some patients complete these at regular intervals, while others may answer them just once.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Germany
Sponsor
iOMEDICO AG
Enrollment target
~1,900 participants
Started
December 2019
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Adrian Binninger
Ravensburg
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.